First-Line Camizestrant For Er+/Her2- Advanced Breast Cancer

First-line camizestrant for ER+/HER2- advanced breast cancer

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancer

Touch Medical Media Services

Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices

CAMBRIA 1: camizestrant ER+/HER2- early breast cancer

First-Line Treatment of HER2-Positive Metastatic Breast Cancer

CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancer

SERENA-2: camizestrant vs fulvestrant in post-menopausal women with advanced ER+/HER- breast cancer

First-Line Treatment of HER2-Positive Metastatic Breast Cancer

Camizestrant may be superior to fulvestrant in patients with HR-positive, HER2-negative BC

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast Conference

Total Health | Oncology

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer

Dr. McIntyre on Eribulin as First-Line Therapy in HER2- Breast Cancer

First-Line ER-Positive Metastatic Breast Cancer Treatments

Expanding options for HER2 advanced breast cancer: Taking trial data to the clinic

Touch Medical Media Services

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Outlook for HR+/HER2- advanced breast cancer treatment

SABCS 2022 highlights

AMEERA-3: amcenestrant does not improve PFS in ER+/HER2- breast cancer

Breast Cancer update - Webinar

NHS England Workforce, Training and Education

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer

PeerView Oncology